Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease

J Clin Oncol. 2010 Oct 20;28(30):e602-4. doi: 10.1200/JCO.2010.29.1682. Epub 2010 Aug 16.

Authors

Usama Gergis¹, Jon Arnason, Rhonda Yantiss, Tsiporah Shore, Usama Wissa, Eric Feldman, Thasia Woodworth

Affiliation

¹ Weill Cornell Medical College, New York, NY, USA.

PMID: 20713858
DOI: 10.1200/JCO.2010.29.1682

No abstract available

Publication types

Case Reports

MeSH terms

Anemia, Aplastic / surgery*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Biopsy
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / immunology
Graft vs Host Disease / pathology
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Intestines / drug effects*
Intestines / immunology
Intestines / pathology
Male
Receptors, Interleukin-6 / antagonists & inhibitors*
Stem Cell Transplantation / adverse effects*
Transplantation, Homologous
Treatment Outcome
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Immunologic Factors
Receptors, Interleukin-6
tocilizumab